Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation operating through two business segments: Innovative Medicine and MedTech. It is one of the world's largest and most diversified healthcare companies, with products spanning oncology, immunology, neuroscience, cardiovascular, and surgical technologies.
Johnson & Johnson initiated a global pharmaceutical manufacturing network restructuring program projected to incur up to $750M in pre-tax restructuring charges.
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more, while BMS posted a Phase 3 win validating its $4.1 billion RayzeBio buy alongside mixed late-stage pulmonary fibrosis data.
Johnson & Johnson's bispecific antibody combination delivers an 89% progression-free survival benefit in a multiple myeloma trial.
Chairman and Chief Executive Officer